Download PDF
Thromb Haemost 2001; 86(02): 509-510
DOI: 10.1055/s-0037-1616078
Commentary
Schattauer GmbH

Taking the Hype out of Hyperfibrinogenaemia?

Fiona R. Green
1   Dept. Cardiovascular Medicine, University of Oxford, Wellcome Trust Centre for Human Genetics, Headington, Oxford, UK
› Author Affiliations
Further Information

Publication History

Publication Date:
12 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Green FR. Fibrinogen polymorphisms and athero-thrombotic disease. Annals of the New York Academy of Sciences. 2001 (in press).
    PubMedGoogle Scholar
  • 2 Suh TT, Holmback K, Jensen NJ, Daugherty CC, Small K, Simon DI. et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9: 2020-33.
    CrossrefPubMedGoogle Scholar
  • 3 Xiao Q, Danton MJ, Witte DP, Kowala MC, Valentine MT, Degen JL. Fibrinogen deficiency is compatible with the development of atherosclerosis in mice. J Clin Invest 1998; 101: 1184-94.
    CrossrefPubMedGoogle Scholar
  • 4 Lou XJ, Boonmark NW, Horrigan FT, Degen JL, Lawn RM. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci USA 1998; 95: 12591-5.
    CrossrefPubMedGoogle Scholar
  • 5 Holmback K, Danton MJ, Suh TT, Daugherty CC, Degen JL. Impaired platelet aggregation and sustained bleeding in mice lacking the fibrinogen motif bound by integrin alpha IIb beta 3. Embo J 1996; 15: 5760-71.
    PubMedGoogle Scholar
  • 6 Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO. et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106: 385-92.
    CrossrefPubMedGoogle Scholar
  • 7 Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL. et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96: 3302-9.
    PubMedGoogle Scholar
  • 8 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR. et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
    PubMedGoogle Scholar
  • 9 Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
    CrossrefPubMedGoogle Scholar
  • 10 Yu S, Sher B, Kudryk B, Redman CM. Intracellular assembly of human fibrinogen. J Biol Chem 1983; 258: 13407-10.
    PubMedGoogle Scholar
  • 11 Roy SN, Mukhopadhyay G, Redman CM. Regulation of fibrinogen assembly. Transfection of Hep G2 cells with B beta cDNA specifically enhances synthesis of the three component chains of fibrinogen. J Biol Chem 1990; 265: 6389-93.
    PubMedGoogle Scholar
  • 12 Rezaee F, Maas A, Verheijen J, Koopman J. Generation and characterization of transgenic mice with overexpression of fibrinogen Bβ-chain and mRNA. Thromb Haemost 1999; 82 (Suppl. 01) 424-5 (Abstr 1343).
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Prunkard D, Cottingham I, Garner I, Bruce S, Dalrymple M, Lasser G. et al. High-level expression of recombinant human fibrinogen in the milk of transgenic mice. Nat Biotechnol 1996; 14: 867-71.
    CrossrefPubMedGoogle Scholar
  • 14 Butler SP, van Cott K, Subrumanian A, Gwazduaskas FC, Velander WH. Current progress in the production of recombinant human fibrinogen in the milk of transgenic animals. Thromb Haemost 1997; 78 State of the Art 537-42.
    Article in Thieme ConnectPubMedGoogle Scholar